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Abstract: CD137 is a member of the TNFR-family with co-stimulatory function. Here we show that it also has many favorable characteristics as a surrogate marker for antigen-specific activation of human
CD8
+ T-cells. While undetectable on unstimulated CD8 + T-cells, it is uniformly upregulated 24h after stimulation on virtually all responding cells regardless of differentiation stage or profile of cytokine secretion, which circumvents limitations of current surrogate markers for defining the repertoire of responding cells based on only individual functions. Antibody-labeled responding CD137 + cells can be easily and efficiently isolated by flow-sorting or magnetic beads to substantially enrich antigen-specific T-cells. To test this approach for epitope discovery, we examined in vitro priming of naïve T-cells from healthy donors to Wilms tumor antigen 1 (WT1), a protein over-expressed in various malignancies. Two overlapping pentadecamers were identified as immunogenic, and further analysis defined WT1 (286) (287) (288) (289) (290) (291) (292) (293) as the minimal amino acid sequence and HLA-Cw07 as the HLA restriction element. In conclusion, this approach appears to be an efficient and sensitive in vitro technique to rapidly identify and isolate
antigen-specific CD8 + T-cells present at low frequencies and displaying heterogenous functional profiles, and does not require prior knowledge of the specific epitopes recognized or the HLArestricting-elements.
Introduction:
Methods to assess antigen-specific CD8 T-cells are essential for understanding cellular immunity under normal and pathologic conditions. Peptide/MHC(pMHC)-multimers 1 accurately detect antigenspecific T-cells, but the knowledge of the immunogenic peptide, its restricting HLA-allele and the availability of the reagent are limiting and rarely sufficient to characterize the breadth of responding cells. Evaluating the repertoire of responses has required identifying-and often subsequently isolatingantigen-specific T-cells using assays that focus on specific functions such as production of a particular cytokine or degranulation in response to antigen 2, 3 . However, such functional assays often only reflect a subset of specifically activated cells, as the in vivo CD8 + T-cell response is composed of functionally diverse cells that cannot be identified by using a single cytokine or the detection of degranulation 4, 5 . For
example, different T-cell subpopulations, such as naïve T-cells, central memory T-cells or T-cells
primed under Th1-or Th2-like conditions, show very heterogenous cytokine profiles, and can therefore only be tracked functionally by using multi-cytokine flow cytometry 6 . A surface molecule that is uniformly upregulated in response to antigen would therefore facilitate the assessment of the complete antigen-specific response. Favorable characteristics of such a surrogate marker would include specific
For personal use only. on October 28, 2017 . by guest www.bloodjournal.org From surface expression following activation over a transient but sufficiently prolonged time period to allow reliable detection, and absent expression if unstimulated and during resting phases. Such an expression pattern would facilitate not only the identification but also the selection of viable, activated T-cells using fluorescence-activated cell-sorting or magnetic beads bound to the specific antibody.
CD137 (4-1BB) was originally identified as a molecule expressed on activated mouse and human CD8
+ and CD4 + T-cells [7] [8] [9] . It is a member of the TNFR-family and mediates co-stimulatory and anti-apoptotic functions, promoting T-cell proliferation and T-cell survival 10, 11 . CD137 has been reported to be upregulated -depending on the T-cell stimulus -from 12h to up to 5 days after stimulation 9,10,12 . Antibody-mediated blockade of the CD137/CD137L interaction has been shown to increase survival of murine allografts 13 , and depletion of human CD137 + donor-derived T-cells after stimulation with allogeneic recipient cells in vitro has recently been described as an approach to reduce alloreactivity 14 . Here we demonstrate that CD137 has many characteristics required for efficient positive selection of specifically activated CD8 + T-cells with a heterogenous functional profile, including memory and naïve responses to viral-(CMV-and HCV-related) and tumor-associated/self-antigens such as MART1/Melan-A 15 and WT1, a transcription factor overexpressed in many malignancies and a potential target for immunotherapy 16 ,17
Peptides
The HLA-A*0201-restricted peptides representing defined epitopes from Melan-A (26-35L) (ELAGIGILTV), WT1 (126-134) (RMFPNAPYL), HIV-1/gag/p17 (77-85) (SLYNTVATL), CMV/pp65 (495) (496) (497) (498) (499) (500) (501) (502) (503) (NLVPMVATV) and CMV/pp65 (417-426) (TPRVTGGGAM) were synthesized by Synpep (Dublin, CA).
HCV/NS3 (1406-1415) (KLVALGINAV) was synthesized by Proimmune (Oxford, UK). A peptide library spanning WT1, consisting of 15-mers overlapping by 11 was purchased from JPT (Berlin, Germany).
Induction of T-cell lines
T-cell lines were generated as previously described with minor modifications 18 . Briefly dendritic cells (DC) were derived from adherent monocytes by culture for 5 days in Cellgenix DC Medium (Cellgenix, Freiburg, Germany) supplemented with 1% human serum, 800IU/ml GM-CSF (Berlex, Seattle,WA) and 1000IU/ml IL-4 (R&D Systems, Minneapolis, MN). On day 3, 1.5ml of fresh medium, supplemented with 1600IU/ml GM-CSF and 1000IU/ml IL4, was added to each well. On day 5, cells were harvested and matured for 24h in fresh DC medium supplemented with a cytokine cocktail of 800IU/ml GM-CSF, 1000IU/ml IL-4, 10ng/ml LPS (derived from E.coli 055:B5, Sigma, St.Louis, MO) and 50IU/ml IFNγ (Intermune, Brisbane, CA). During the maturation phase, DC were pulsed with 10µg/ml of peptide. For experiments using the peptide library, each individual peptide was at a concentration of 1.8µg/ml. Naïve CD8 + T-cells were obtained by depleting CD45RO + cells from PBMC using anti-CD45RO microbeads (Miltenyi Biotec, Auburn, CA), followed by positive selection using anti-CD8
microbeads. This approach resulted in >95% pure CD45RO -CD8 + populations.
Mature, peptide pulsed DC were washed and incubated with CD8 + cells at a ratio of 1:2 -1:10 in complete T-cell medium supplemented with 100µM 1-methyltryptophan (Sigma) and Each distributed in 96-well v-bottom plates or 24-well-plates (2x10 5 to 5x10 5 T-cells/well, respectively). On day 4, IL-7 and IL-15 (R&D Systems, f.c. 5ng/ml) were added with medium. Cell lines were supplemented every 2-3 days with medium and cytokines.
For restimulation, autologous PBMC were pulsed with peptide (10µg/ml) for 2h and irradiated (30Gy). Each T-cell line was harvested, resuspended in medium without cytokines, and mixed with 1x10 6 PBMC in a 6-well plate. 24h later, 2ml of medium was added containing cytokines (f.c. 50IU/ml IL-2, 5ng/ml IL-7, and 5ng/ml IL-15). T-cell cloning was performed as described recently 18 .
Immunophenotyping and pMHC-multimer staining
Antibodies used for immunophenotyping include: anti- CD8-FITC or -PE, anti-CD69-PE, anti-CD25-PE or -FITC, anti-CD137-PE or -APC, anti-CD134-PE, anti-HLA-DR-PE, anti-CD38-PE (all from BD Pharmingen, San Diego, CA). pMHC-multimer staining was performed using APC-labeled pMHC-multimers (Proimmune, UK) and incubating the cells for 20 min at room temperature (RT), followed by 20 min incubation at RT with anti-CD8 antibody. Dead cells were excluded using 7-AAD (BD).
Intracellular cytokine staining and CD107a mobilization shift assay
The assay was performed as described 3, 19 . Briefly, 2x10 5 T-cells were stimulated for 5h in 96-well plates using 4x10 5 peptide-pulsed T2 cells or DC. CD107a-FITC (BD) and 10ug/ml brefeldin A (Sigma) was added at the beginning of the stimulation period. After 5h cells were stained for CD107a and co-stained for CD8. Cells were fixed, permeabilized and stained with antibodies against IFNγ, TNFα or IL-2 (BD), using FIX/PERM and PERM/Wash solution (BD).
CD137 enrichment assay, IFNγ-secretion assay, chromium release assay
T-cell lines were generated from naïve T-cells as described above. Twenty-four hours after restimulation, T-cells were washed and stained for 20 min on ice with anti-CD137-APC (5ul/100ul) (BD). After washing, the cells were incubated with anti-APC-microbeads (Miltenyi) and selected using MS or LS columns.
The IFNγ-secretion assay (Miltenyi) was performed as described by the manufacturer. The peptide stimulus was the same as for CD137 enrichment, with a stimulation period of 4h to detect peak IFNγ-responses. The cells were allowed to secrete IFNγ for 45min, and then cooled in the appropriate volume of cold buffer. All further procedures were performed on ice.
Chromium release assays were performed as described elsewhere 18 .
Statistics
Pearson correlation (two-tailed) for data derived from two methods was calculated using GraphPadPrism software. For each analysis, the p-value and the coefficient of determination (r 2 ) are indicated.
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Results:
Baseline level and kinetics of CD137 expression allows for the characterization of specifically
activated CD8 + T-cells
To identify surface markers that could serve as surrogate markers for functional activation, a Tcell clone specific for the heteroclitic HLA-A*0201-restricted epitope of MelanA/MART1 (26-35L) that had entered a resting phase at the end of a 14-day expansion cycle was stimulated with peptide-pulsed T2-cells as APC. Twenty-four hours after stimulation, CD69, CD25, CD137, CD38 and HLA-DR were all upregulated ( Figure 1a ). Among these, CD69, CD25 and CD137 exhibited a large enough shift in fluorescence intensity to permit separation of activated cells from unstimulated cells. CD137 expression was increased after 5 hours, peaked by 24 hours and then gradually declined during the period from 48-72 hours (Figure 1b ). Among the other markers, only CD25 showed similar kinetics to CD137, whereas expression of CD69, CD38 and HLA-DR was more variable, usually peaking after 6h but then quickly returning to baseline levels. CD134 was still negative at 24h, but increased slightly by 48h. Among the three markers that were upregulated sufficiently for specific detection -CD25, CD137 and CD69 -, only CD137 was not expressed on unstimulated, resting T-cells, which is essential if the marker is to be used for a bead-based selection method. Similar results were obtained for 5 different T-cell clones with varying specificities (data not shown).
As CD25, CD137 and CD69 were most informative, their expression was next analyzed in a Melan-A (26-35L) specific T-cell line to assess baseline expression and upregulation in a polyclonal population, generated by two rounds of stimulation. Twenty-four hours after the third stimulation the cells were stained using PE-labelled mAbs for the respective markers and co-stained with anti-CD8-antibody and the pMHC-multimer. As expected, TCR downregulation in response to antigen hampered pMHC-multimer staining, with fewer multimer + cells and lower intensity staining detected at 24 hours compared to pre-stimulation (Figure 1c ), making this unreliable for tracking antigen-specific cells following activation. All 3 markers were strongly upregulated on a large fraction of cells. However, similar to what had been observed with clones, baseline expression was minimal for CD137, whereas low or intermediate expression for CD69 and CD25 respectively was observed in unstimulated cells (Figure 1c) . In a parallel set of samples, triple staining for CD25, CD69 and CD137 was performed.
CD137
+ cells were nearly uniformly triple positive (96%), whereas gating on CD69 + or CD25 + cells defined more heterogeneous populations with 18% and 17% respectively negative for CD137, which may represent non-specifically stimulated cells in culture expressing the observed higher baseline levels
For personal use only. on October 28, 2017 . by guest www.bloodjournal.org From of CD69 and CD25 (data not shown). Of note antigen-independent upregulation of CD137 in response to IL-15, as has been reported with high doses (100ng/ml) 20 , was not observed in the culture systems used for this study, as a lower more physiologic dose (5ng/ml) of IL-15 was routinely used. Thus, CD137 appeared to have the most favorable expression profile among the markers tested for identifying specifically activated CD8 + T-cells.
CD137 expression correlates with functional activation of CD8 T-cell clones and lines
As CD137 upregulation is a function of T-cell activation, the threshold for inducing CD137
expression was compared to IFNγ and TNFα production following stimulation with titrated amounts of the cognate antigen. Two T-cell clones, clone 88 specific for Melan-A (26-35L) , and clone 10 specific for WT1 (126) (127) (128) (129) (130) (131) (132) (133) (134) , were stimulated with T2-cells pulsed with titrated amounts of peptide. For optimal results, these functional assays require different incubation times -therefore samples were set-up in parallel and cytokine production assessed after 5h and CD137 expression determined after 24h of incubation. The cells showed comparable activation thresholds for cytokine production and CD137 expression, with similar peptide concentrations necessary to attain half-maximal activation (Clone 88 with an EC 50 [M] for CD137=2.5x10 -9 , IFNγ=3.7x10 -9 , and TNFα=1.5x10 The HLA-A*0201 restricted heteroclitic Melan-A/MART1 (26-35L) epitope is unique in that a fairly high precursor frequency of naïve antigen-specific T-cells in healthy individuals can often be found 15 . Therefore, to examine a prototypic in vitro response with a more typical precursor frequency, responses to an A*0201-restricted epitope derived from the non-structural protein 3 of the hepatitis C virus (NS3 (1406-1415) ) 21 were studied in cell lines derived from healthy, HCV sero-negative individuals.
To compare CD137 expression with other standard assays used for identification of activated T-cells in 
Viable CD137 + T-cells can be easily isolated and are antigen-specific
Without knowledge of the recognized epitope and an available tetramer, the isolation and expansion of T-cells specific for a selected target or antigen for either analysis or use in adoptive therapy can be difficult. In initial experiments, we were unsuccessful in generating robust manipulable responses to a panel of candidate peptides derived from the weakly immunogenic WT1 antigen, using the IFNγ-secretion assay to isolate cells (data not shown). Therefore, as an alternative strategy, we examined selection of cells that demonstrated upregulation of CD137 following antigen stimulation for enrichment of responding T-cells from T-cell cultures containing an initially low frequency of antigen-specific Tcells. Before assessing this technique for epitope discovery of unknown antigens, as described later for WT1, we wanted to validate the approach using a model foreign antigen known to induce responses. A polyclonal T-cell response was generated against the HCV/NS3 (1406-1415) -epitope by stimulation of naïve CD8 + T-cells from an HCV seronegative donor with peptide-pulsed DC, and culture for 1 week in medium containing IL-7 and IL-15 as previously described 18 . CD45RO -CD8 + cells were routinely used as the naïve starting population, but a similar T-cell response against this epitope could also be induced by using CD62L + CD45RO -CD8 + T-cells or CD45RA + CCR7 + CD8 + T-cells. In contrast, HCV/NS3 (1406-1415) specific T cells could not be generated from CD45RO + T-cells (data not shown). The primed cells were restimulated and enriched for CD137 + cells 24h later using magnetic beads, and placed back in cytokine-containing medium for 8 days to allow expansion and re-expression of the TCR before being the T-cells (20 days after cloning), the growing clones were screened using pMHC-multimers. In the CD137 + group, 250 of 480 plated wells contained growing cells. 67% of these wells contained clones that were HCV/NS3 (1406-1415) -specific (overall specific cloning efficiency: 35%). In contrast only 75 of 480 wells from the un-enriched control group showed cell growth, with only 15% of these wells containing clones that were pMHC-multimer + (overall specific cloning efficiency 2.3%) ( Table 2) .
CD137 is a more uniform marker of antigen-specific activation than monitoring production of only a single cytokine.
Methods based on cytokine secretion following activation are often used to enrich antigenspecific CD8 + cells, and we compared the utility of the IFNγ-secretion method with the CD137- Unlike the CD8 memory response to CMV in which IFNγ is the dominant activation-induced cytokine 22 , naïve T-cells are known to secret low quantities of IFNγ, a function which is acquired later after differentiation into Tc1-like effector cells. It is therefore difficult to isolate naïve CD8 + T-cells using the IFNγ-secretion assay as has been described before 23 . Indeed after stimulating naïve T-cells with the Melan-A-peptide, we were unable to enrich for antigen-specific cells using the IFNγ-secretion method (data not shown). However when PBMC were stimulated directly ex vivo with the Melan-A peptide and CD137 + cells isolated 24h later and cultured for 1 week, 36% of the cells were pMHC- 
Enrichment of CD137+ T-cells upon antigen-stimulation includes T-cells with lytic capacity against antigen+ tumor cells
We next wanted to know, if the isolated and enriched T-cell population includes T-cells that were able to recognize endogeneously processed and presented antigen by tumor cells. A Melan-A specific T-cell line was generated by 2 rounds of in vitro stimulation, resulting in 8% pMHC-multimer+ T-cells (Figure 5a(i) ). This line was restimulated with peptide-pulsed PBMC and CD137 + cells were selected 24h later (Figure 5a (ii)). When these cells were further expanded for one week, 87% of the Tcells were Melan-A multimer+ (Figure 5a(iii)) . This line was then tested for recognition of the HLA- The CD137 assay as a tool for adoptive immunotherapy and epitope discovery
In the context of malignancy, a selection procedure that does not require the exact knowledge of the epitope or the HLA-restriction element, could be used to identify novel antigens and broaden the spectrum of patients eligible for immunotherapy trials 24 . WT1, a pro-oncogenic protein over-expressed in hematologic and oncologic malignancies 16 , is being evaluated as a target protein for (Table 3) . In a T-cell line, generated from a second donor, who shared only the Cw07-allele with the original donor, the minimal essential amino acid sequence was then determined . The WT1 (286-294) (YRIHTHGVF) 9-mer induced a strong
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IFNγ response, whereas loss of tyrosine in position 1 or the phenylalanine in position 9 described as an anchor in the binding motif for HLA-Cw07 28 abrogated recognition ( Figure 6c and Table 4 ).
Discussion:
The biological role of CD137 to provide a survival signal to activated T-cells has been demonstrated in vivo and in vitro 9, 29 .
Here we describe a novel use of CD137 based on the kinetics of expression following antigen recognition to identify and expand antigen-specific CD8 + cells. This new application has several advantages over alternative techniques for evaluating CD8 + T-cell responses: 1)
it defines a broad and, based on pMHC multimer binding, nearly complete repertoire of the antigenspecific CD8 + T-cells in a heterogeneous population, which cannot be achieved by analyzing the production of a single cytokine alone; 2) it allows the detection, isolation and subsequently the rapid expansion of antigen-specific CD8 + cells even if present initially at a very low precursor frequency; 3) it can be performed independent of knowledge of the immunogenic epitopes and MHC-restriction elements; 4) it correlates well with already established assays like CFC; and 5) it requires a simple staining procedure of a surface antigen that has a relatively long window of upregulated expression after stimulation.
Exploiting the characteristics of CD137 expression provides a broader picture of the CD8 + T-cell population responding to antigen than the analysis of a single cytokine alone, as demonstrated using naïve T-cells. Based on this data and preliminary data using polarizing priming conditions, such as priming in the presence of exogenous IL-4 (not shown), CD137 appears to serve as a uniform marker for different T-cell subsets such as central memory cells or CD8 + T-cells primed under Th2/Tc2-conditions.
Screening for responsive CD137 + T-cell populations, followed by analysis of production of different cytokines should enhance the detection, monitoring and selection of diverse responding CD8 + T-cell subpopulations, and could facilitate vaccine development requiring quantitative and qualitative characterization of the CD8 + T-cell response 6, 30 .
Our own preliminary data, as well as the work done by Wehler et al. studying depletion of alloreactive T-cells 14 , indicate that CD137 is also specifically upregulated on CD4 + T-cells. However further work is required to define specificity and kinetic of CD137 upregulation on CD4 + cells and its comparison with selection methods based on expression of CD154.
31,32
The ability to detect and expand ex vivo high-avidity CD8 + T-cells specific for candidate tumorassociated antigens is essential not only for pursuing adoptive T-cell immunotherapy but also for These reflect optimal time-points for detecting each of these events). b) 6 separate T-cell lines specific for the NS3 (1406-1415) -epitope of HCV were generated, and assessed for cytokine production and degranulation after 5h of stimulation, and CD137 expression after 24h and pMHC multimer staining of the unstimulated sample. Pearson correlation (two-tailed) was calculated and the p-value and the coefficient of determination (r 2 ) appear in each plot. c) PBMC from 7 CMV + /HLA-A*0201 + donors were thawed, rested overnight and analyzed for pMHC multimer staining, cytokine productionanddegranulation after 5h of stimulation and CD137 expression at 24h. P-value; r 2 appear in each plot. 
